News

The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main

The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is

The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026

The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial,

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix’s expertise in radiopharmaceutical platforms, global

According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for

Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan & Lee. Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the

The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in